A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage–mediated, vascular-targeted suicide gene transfer
Open Access
- 1 August 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 8 (8) , 2383-2391
Abstract
Suicide gene transfer is the most commonly used cytotoxic approach in cancer gene therapy; however, a successful suicide gene therapy depends on the generation of efficient targeted systemic gene delivery vectors. We recently reported that selective systemic delivery of suicide genes such as herpes simplex virus thymidine kinase (HSVtk) to tumor endothelial cells through a novel targeted adeno-associated virus/phage vector leads to suppression of tumor growth. This marked effect has been postulated to result primarily from the death of cancer cells by hypoxia following the targeted disruption of tumor blood vessels. Here, we investigated whether an additional mechanism of action is involved. We show that there is a heterotypic “bystander” effect between endothelial cells expressing the HSVtk suicide gene and tumor cells. Treatment of cocultures of HSVtk-transduced endothelial cells and non-HSVtk-transduced tumor cells with ganciclovir results in the death of both endothelial and tumor cells. Blocking of this effect by 18α-glycyrrhetinic acid indicates that gap junctions between endothelial and tumor cells are largely responsible for this phenomenon. Moreover, the observed bystander killing is mediated by connexins 43 and 26, which are expressed in endothelial and tumor cell types. Finally, this heterotypic bystander effect is accompanied by a suppression of tumor growth in vivo that is independent of primary gene transfer into host-derived tumor vascular endothelium. These findings add an alternative nonmutually exclusive and potentially synergistic cytotoxic mechanism to cancer gene therapy based on targeted adeno-associated virus/phage and further support the promising role of nonmalignant tumor stromal cells as therapeutic targets. [Mol Cancer Ther 2009;8(8):2383–91]Keywords
This publication has 45 references indexed in Scilit:
- Tumor vasculature‐targeted delivery of tumor necrosis factor‐α*Cancer, 2008
- A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imagingProceedings of the National Academy of Sciences, 2008
- Design and construction of targeted AAVP vectors for mammalian cell transductionNature Protocols, 2007
- Efficient infection of tumor endothelial cells by a capsid-modified adenovirusGene Therapy, 2005
- AAV display—homing in on the targetNature Biotechnology, 2003
- Purified herpes simplex virus thymidine kinase retroviral particles:Cancer Gene Therapy, 2002
- AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor depositsGene Therapy, 2001
- The role of cellular- and prodrug-associated factors in the bystander effect induced by the Varicella zoster and Herpes simplex viral thymidine kinases in suicide gene therapyCancer Gene Therapy, 2000
- Tentative Novel Mechanism of the Bystander Effect in Glioma Gene Therapy with HSV-TK/GCV SystemBiochemical and Biophysical Research Communications, 1999
- The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in ratsJournal of Neurosurgery, 1994